Delivery of antidepressants through an inhalation route

A composition for delivery of nefazodone consisting of a condensation aerosol

• a. formed by volatilizing a thin layer of nefazodone on a solid support, having the surface texture of a metal foil, to a temperature sufficient to produce a heated vapor of nefazodone and condensing the heated vapor of nefazodone to form condensation aerosol particles,
• b. wherein said condensation aerosol particles are characterized by less than 5% nefazodone degradation products, and
• c. the condensation aerosol has an MMAD of less than 3 microns.

A composition for delivery of perphenazine consisting of a condensation aerosol

• a. formed by volatilizing a thin layer of perphenazine on a solid support, having the surface texture of a metal foil, to a temperature sufficient to produce a heated vapor of perphenazine and condensing the heated vapor of perphenazine to form condensation aerosol particles,
• b. wherein said condensation aerosol particles are characterized by less than 5% perphenazine degradation products, and
• c. the condensation aerosol has an MMAD of less than 3 microns.

A composition for delivery of trazodone consisting of a condensation aerosol

• a. formed by volatilizing a thin layer of trazodone on a solid support, having the surface texture of a metal foil, to a temperature sufficient to produce a heated vapor of trazodone and condensing the heated vapor of trazodone to form condensation aerosol particles,
• b. wherein said condensation aerosol particles are characterized by less than 5% trazodone degradation products, and
• c. the condensation aerosol has an MMAD of less than 3 microns.

A composition for delivery of naratriptan consisting of a condensation aerosol

• a. formed by volatilizing a thin layer of trimipramine on a solid support, having the surface texture of a metal foil, to a temperature sufficient to produce a heated vapor of trimipramine and condensing the heated vapor of trimipramine to form condensation aerosol particles,
• b. wherein said condensation aerosol particles are characterized by less than 5% trimipramine degradation products, and
• c. the condensation aerosol has an MMAD of less than 3 microns.

A composition for delivery of venlafaxine consisting of a condensation aerosol

• a. formed by volatilizing a thin layer of venlafaxine on a solid support, having the surface texture of a metal foil, to a temperature sufficient to produce a heated vapor of venlafaxine and condensing the heated vapor of venlafaxine to form condensation aerosol particles,
• b. wherein said condensation aerosol particles are characterized by less than 5% venlafaxine degradation products, and
• c. the condensation aerosol has an MMAD of less than 3 microns.

A composition for delivery of tranylcypromine consisting of a condensation aerosol

• a. formed by volatilizing a thin layer of tranylcypromine on a solid support, having the surface texture of a metal foil, to a temperature sufficient to produce a heated vapor of tranylcypromine and condensing the heated vapor of tranylcypromine to form condensation aerosol particles,
• b. wherein said condensation aerosol particles are characterized by less than 5% tranylcypromine degradation products, and
• c. the condensation aerosol has an MMAD of less than 3 microns.

A composition for delivery of citalopram consisting of a condensation aerosol

• a. formed by volatilizing a thin layer of citalopram on a solid support, having the surface texture of a metal foil, to a temperature sufficient to produce a heated vapor of citalopram and condensing the heated vapor of citalopram to form condensation aerosol particles,
• b. wherein said condensation aerosol particles are characterized by less than 5% citalopram degradation products, and
• c. the condensation aerosol has an MMAD of less than 3 microns.

A composition for delivery of fluoxetine consisting of a condensation aerosol

• a. formed by volatilizing a thin layer of fluoxetine on a solid support, having the surface texture of a metal foil, to a temperature sufficient to produce a heated vapor of fluoxetine and condensing the heated vapor of fluoxetine to form condensation aerosol particles,
• b. wherein said condensation aerosol particles are characterized by less than 5% fluoxetine degradation products, and
• c. the condensation aerosol has an MMAD of less than 3 microns.

A composition for delivery of fluvoxamine consisting of a condensation aerosol

• a. formed by volatilizing a thin layer of fluvoxamine on a solid support, having the surface texture of a metal foil, to a temperature sufficient to produce a heated vapor of fluvoxamine and condensing the heated vapor of fluvoxamine to form condensation aerosol particles,
• b. wherein said condensation aerosol particles are characterized by less than 5% fluvoxamine degradation products, and
• c. the condensation aerosol has an MMAD of less than 3 microns.

A composition for delivery of mirtazepine consisting of a condensation aerosol

• a. formed by volatilizing a thin layer of mirtazepine on a solid support, having the surface texture of a metal foil, to a temperature sufficient to produce a heated vapor of mirtazepine and condensing the heated vapor of mirtazepine to form condensation aerosol particles,
• b. wherein said condensation aerosol particles are characterized by less than 5% mirtazepine degradation products, and
• c. the condensation aerosol has an MMAD of less than 3 microns.

A composition for delivery of paroxetine consisting of a condensation aerosol

• a. formed by volatilizing a thin layer of paroxetine on a solid support, having the surface texture of a metal foil, to a temperature sufficient to produce a heated vapor of paroxetine and condensing the heated vapor of paroxetine to form condensation aerosol particles,
• b. wherein said condensation aerosol particles are characterized by less than 5% paroxetine degradation products, and
• c. the condensation aerosol has an MMAD of less than 3 microns.

A composition for delivery of sertraline consisting of a condensation aerosol

• a. formed by volatilizing a thin layer of sertraline on a solid support, having the surface texture of a metal foil, to a temperature sufficient to produce a heated vapor of sertraline and condensing the heated vapor of sertraline to form condensation aerosol particles,
• b. wherein said condensation aerosol particles are characterized by less than 5% sertraline degradation products, and
• c. the condensation aerosol has an MMAD of less than 3 microns.

A composition for delivery of amoxipine consisting of a condensation aerosol

• a. formed by volatilizing a thin layer of amoxipine on a solid support, having the surface texture of a metal foil, to a temperature sufficient to produce a heated vapor of amoxipine and condensing the heated vapor of amoxipine to form condensation aerosol particles,
• b. wherein said condensation aerosol particles are characterized by less than 5% amoxipine degradation products, and
• c. the condensation aerosol has an MMAD of less than 3 microns.

A composition for delivery of clomipramine consisting of a condensation aerosol

• a. formed by volatilizing a thin layer of clomipramine on a solid support, having the surface texture of a metal foil, to a temperature sufficient to produce a heated vapor of clomipramine and condensing the heated vapor of clomipramine to form condensation aerosol particles,
• b. wherein said condensation aerosol particles are characterized by less than 5% clomipramine degradation products, and
• c. the condensation aerosol has an MMAD of less than 3 microns.

A composition for delivery of doxepin consisting of a condensation aerosol

• a. formed by volatilizing a thin layer of doxepin on a solid support, having the surface texture of a metal foil, to a temperature sufficient to produce a heated vapor of doxepin and condensing the heated vapor of doxepin to form condensation aerosol particles,
• b. wherein said condensation aerosol particles are characterized by less than 5% doxepin degradation products, and
• c. the condensation aerosol has an MMAD of less than 3 microns.

A composition for delivery of imipramine consisting of a condensation aerosol

• a. formed by volatilizing a thin layer of imipramine on a solid support, having the surface texture of a metal foil, to a temperature sufficient to produce a heated vapor of imipramine and condensing the heated vapor of imipramine to form condensation aerosol particles,
• b. wherein said condensation aerosol particles are characterized by less than 5% imipramine degradation products, and
• c. the condensation aerosol has an MMAD of less than 3 microns.

A composition for delivery of maprotiline consisting of a condensation aerosol

• a. formed by volatilizing a thin layer of maprotiline on a solid support, having the surface texture of a metal foil, to a temperature sufficient to produce a heated vapor of maprotiline and condensing the heated vapor of maprotiline to form condensation aerosol particles,
• b. wherein said condensation aerosol particles are characterized by less than 5% maprotiline degradation products, and
• c. the condensation aerosol has an MMAD of less than 3 microns.

A composition for delivery of nortryptiline consisting of a condensation aerosol

• a. formed by volatilizing a thin layer of nortryptiline on a solid support, having the surface texture of a metal foil, to a temperature sufficient to produce a heated vapor of nortryptiline and condensing the heated vapor of nortryptiline to form condensation aerosol particles,
• b. wherein said condensation aerosol particles are characterized by less than 5% nortryptiline degradation products, and
• c. the condensation aerosol has an MMAD of less than 3 microns.

A composition for delivery of valproic acid consisting of a condensation aerosol

• a. formed by volatilizing a thin layer of valproic acid on a solid support, having the surface texture of a metal foil, to a temperature sufficient to produce a heated vapor of valproic acid and condensing the heated vapor of valproic acid to form condensation aerosol particles,
• b. wherein said condensation aerosol particles are characterized by less than 5% valproic acid degradation products, and
• c. the condensation aerosol has an MMAD of less than 3 microns.

A composition for delivery of protryptyline consisting of a condensation aerosol

• a. formed by volatilizing a thin layer of protryptyline on a solid support, having the surface texture of a metal foil, to a temperature sufficient to produce a heated vapor of protryptyline and condensing the heated vapor of protryptyline to form condensation aerosol particles,
• b. wherein said condensation aerosol particles are characterized by less than 5% protryptyline degradation products, and
• c. the condensation aerosol has an MMAD of less than 3 microns.

A method of producing bupropion in an aerosol form comprising:

• a. heating a thin layer of bupropion on a solid support, having the surface texture of a metal foil, to a temperature sufficient to volatilize the bupropion to form a heated vapor of the bupropion, and
• b. during said heating, passing air through the heated vapor to produce aerosol particles of the bupropion comprising less than 5% bupropion degradation products, and an aerosol having an MMAD of less than 3 microns.

A method of producing nefazodone in an aerosol form comprising:

• a. heating a thin layer of nefazodone on a solid support, having the surface texture of a metal foil, to a temperature sufficient to volatilize the nefazodone to form a heated vapor of the nefazodone, and
• b. during said heating, passing air through the heated vapor to produce aerosol particles of the nefazodone comprising less than 5% nefazodone degradation products, and an aerosol having an MMAD of less than 3 microns.

A method of producing perphenazine in an aerosol form comprising:

• a. heating a thin layer of perphenazine on a solid support, having the surface texture of a metal foil, to a temperature sufficient to volatilize the perphenazine to form a heated vapor of the perphenazine, and
• b. during said heating, passing air through the heated vapor to produce aerosol particles of the perphenazine comprising less than 5% perphenazine degradation products, and an aerosol having an MMAD of less than 3 microns.

A method of producing trazodone in an aerosol form comprising:

• a. heating a thin layer of trazodone on a solid support, having the surface texture of a metal foil, to a temperature sufficient to volatilize the trazodone to form a heated vapor of the trazodone, and
• b. during said heating, passing air through the heated vapor to produce aerosol particles of the trazodone comprising less than 5% trazodone degradation products, and an aerosol having an MMAD of less than 3 microns.

A method of producing trimipramine in an aerosol form comprising:

• a. heating a thin layer of trimipramine on a solid support, having the surface texture of a metal foil, to a temperature sufficient to volatilize the trimipramine to form a heated vapor of the trimipramine, and
• b. during said heating, passing air through the heated vapor to produce aerosol particles of the trimipramine comprising less than 5% trimipramine degradation products, and an aerosol having an MMAD of less than 3 microns.

A method of producing venlafaxine in an aerosol form comprising:

• a. heating a thin layer of venlafaxine on a solid support, having the surface texture of a metal foil, to a temperature sufficient to volatilize the venlafaxine to form a heated vapor of the venlafaxine, and
• b. during said heating, passing air through the heated vapor to produce aerosol particles of the venlafaxine comprising less than 5% venlafaxine degradation products, and an aerosol having an MMAD of less than 3 microns.

A method of producing tranylcypromine in an aerosol form comprising:

• a. heating a thin layer of tranylcypromine on a solid support, having the surface texture of a metal foil, to a temperature sufficient to volatilize the tranylcypromine to form a heated vapor of the tranylcypromine, and
• b. during said heating, passing air through the heated vapor to produce aerosol particles of the tranylcypromine comprising less than 5% tranylcypromine degradation products, and an aerosol having an MMAD of less than 3 microns.

A method of producing citalopram in an aerosol form comprising:

• a. heating a thin layer of citalopram on a solid support, having the surface texture of a metal foil, to a temperature sufficient to volatilize the citalopram to form a heated vapor of the citalopram, and
• b. during said heating, passing air through the heated vapor to produce aerosol particles of the citalopram comprising less than 5% citalopram degradation products, and an aerosol having an MMAD of less than 3 microns.

A method of producing fluoxetine in an aerosol form comprising:

• a. heating a thin layer of fluoxetine on a solid support, having the surface texture of a metal foil, to a temperature sufficient to volatilize the fluoxetine to form a heated vapor of the fluoxetine, and
• b. during said heating, passing air through the heated vapor to produce aerosol particles of the fluoxetine comprising less than 5% fluoxetine degradation products, and an aerosol having an MMAD of less than 3 microns.

A method of producing fluvoxamine in an aerosol form comprising:

• a. heating a thin layer of fluvoxamine on a solid support, having the surface texture of a metal foil, to a temperature sufficient to volatilize the fluvoxamine to form a heated vapor of the fluvoxamine, and
• b. during said heating, passing air through the heated vapor to produce aerosol particles of the fluvoxamine comprising less than 5% fluvoxamine degradation products, and an aerosol having an MMAD of less than 3 microns.

A method of producing mirtazepine in an aerosol form comprising:

• a. heating a thin layer of mirtazepine on a solid support, having the surface texture of a metal foil, to a temperature sufficient to volatilize the mirtazepine to form a heated vapor of the mirtazepine, and
• b. during said heating, passing air through the heated vapor to produce aerosol particles of the mirtazepine comprising less than 5% mirtazepine degradation products, and an aerosol having an MMAD of less than 3 microns.

A method of producing paroxetine in an aerosol form comprising:

• a. heating a thin layer of paroxetine on a solid support, having the surface texture of a metal foil, to a temperature sufficient to volatilize the paroxetine to form a heated vapor of the paroxetine, and
• b. during said heating, passing air through the heated vapor to produce aerosol particles of the paroxetine comprising less than 5% paroxetine degradation products, and an aerosol having an MMAD of less than 3 microns.

A method of producing sertraline in an aerosol form comprising:

• a. heating a thin layer of sertraline on a solid support, having the surface texture of a metal foil, to a temperature sufficient to volatilize the sertraline to form a heated vapor of the sertraline, and
• b. during said heating, passing air through the heated vapor to produce aerosol particles of the sertraline comprising less than 5% sertraline degradation products, and an aerosol having an MMAD of less than 3 microns.

A method of producing amoxapine in an aerosol form comprising:

• a. heating a thin layer of amoxapine on a solid support, having the surface texture of a metal foil, to a temperature sufficient to volatilize the amoxapine to form a heated vapor of the amoxapine, and
• b. during said heating, passing air through the heated vapor to produce aerosol particles of the amoxapine comprising less than 5% amoxapine degradation products, and an aerosol having an MMAD of less than 3 microns.

A method of producing clomipramine in an aerosol form comprising:

• a. heating a thin layer of clomipramine on a solid support, having the surface texture of a metal foil, to a temperature sufficient to volatilize the clomipramine to form a heated vapor of the clomipramine, and
• b. during said heating, passing air through the heated vapor to produce aerosol particles of the clomipramine comprising less than 5% clomipramine degradation products, and an aerosol having an MMAD of less than 3 microns.

A method of producing doxepin in an aerosol form comprising:

• a. heating a thin layer of doxepin on a solid support, having the surface texture of a metal foil, to a temperature sufficient to volatilize the doxepin to form a heated vapor of the doxepin, and
• b. during said heating, passing air through the heated vapor to produce aerosol particles of the doxepin comprising less than 5% doxepin degradation products, and an aerosol having an MMAD of less than 3 microns.

A method of producing imipramine in an aerosol form comprising:

• a. heating a thin layer of imipramine on a solid support, having the surface texture of a metal foil, to a temperature sufficient to volatilize the imipramine to form a heated vapor of the imipramine, and
• b. during said heating, passing air through the heated vapor to produce aerosol particles of the imipramine comprising less than 5% imipramine degradation products, and an aerosol having an MMAD of less than 3 microns.

A method of producing maprotiline in an aerosol form comprising:

• a. heating a thin layer of maprotiline on a solid support, having the surface texture of a metal foil, to a temperature sufficient to volatilize the maprotiline to form a heated vapor of the maprotiline, and
• b. during said heating, passing air through the heated vapor to produce aerosol particles of the maprotiline comprising less than 5% maprotiline degradation products, and an aerosol having an MMAD of less than 3 microns.

A method of producing nortryptiline in an aerosol form comprising:

• a. heating a thin layer of nortryptiline on a solid support, having the surface texture of a metal foil, to a temperature sufficient to volatilize the nortryptiline to form a heated vapor of the nortryptiline, and
• b. during said heating, passing air through the heated vapor to produce aerosol particles of the nortryptiline comprising less than 5% nortryptiline degradation products, and an aerosol having an MMAD of less than 3 microns.

A method of producing valproic acid in an aerosol form comprising:

• a. heating a thin layer of valproic acid on a solid support, having the surface texture of a metal foil, to a temperature sufficient to volatilize the valproic acid to form a heated vapor of the valproic acid, and
• b. during said heating, passing air through the heated vapor to produce aerosol particles of the valproic acid comprising less than 5% valproic acid degradation products, and an aerosol having an MMAD of less than 3 microns.

A method of producing protryptyline in an aerosol form comprising:

• a. heating a thin layer of protryptyline on a solid support, having the surface texture of a metal foil, to a temperature sufficient to volatilize the protryptyline to form a heated vapor of the protryptyline, and
• b. during said heating, passing air through the heated vapor to produce aerosol particles of the protryptyline comprising less than 5% protryptyline degradation products, and an aerosol having an MMAD of less than 3 microns.